Open Access
Article
Bone morphogenetic protein and bone metastasis, implication and therapeutic potential
Lin Ye1,Malcolm D Mason1,Wen G Jiang1
1
Metastasis and Angiogenesis Research Group, Cardiff University School of Medicine, Cardiff CF14 4XN, UK. yel@cf.ac.uk
DOI: 10.2741/3725 Volume 16 Issue 3, pp.865-897
Published: 01 January 2011
(This article belongs to the Special Issue Bone metastasis, the molecular, cellular and clinical prospects)
Abstract

Bone metastasis is one of the most common and severe complications in advanced malignancies, particularly in the three leading cancers; breast cancer, prostate cancer and lung cancer. It is currently incurable and causes severe morbidities, including bone pain, hypercalcemia, pathological fracture, spinal cord compression and consequent paralysis. However, the mechanisms underlying the development of bone metastasis remain largely unknown. Bone morphogenetic proteins (BMPs) belong to the TGF-beta superfamily and are pluripotent factors involved in the regulation of embryonic development and postnatal homeostasis of various organs and tissues, by controlling cellular differentiation, proliferation and apoptosis. Since they are potent regulators for bone formation, there is an increasing interest to investigate BMPs and their roles in bone metastasis. BMPs have been implicated in various neoplasms, at both primary and secondary tumors, particularly skeletal metastasis. Recently studies have also suggested that BMP signaling and their antagonists play pivotal roles in bone metastasis. In this review, we discuss the current knowledge of aberrations of BMPs which have been indicated in tumor progression, and particularly in the development of bone metastasis.

Share and Cite
Lin Ye, Malcolm D Mason, Wen G Jiang. Bone morphogenetic protein and bone metastasis, implication and therapeutic potential. Frontiers in Bioscience-Landmark. 2011. 16(3); 865-897.